{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2017"],"condition":["MSI","Chemotherapy","Activated Protein C Resistance","Resistance, APC","Colorectal carcinoma","Colorectal Neoplasms","ColoRectal Cancer"],"disease":["Colorectal Carcinoma","Msi","Chemotherapy","Activated Protein C Resistance","Resistance, Apc","Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2231288"],"location":["Netherlands","Belgium","Italy","Spain"],"study_start_month":["11"],"keyword":["Colorectal","Atezolizumab","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Terminated"],"additional_accession":[]},"is_claimable":false,"name":"Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer","description":"The primary objective of this study is to determine the anti-tumor activity, as measured by overall response rate (ORR) of atezolizumab in combination with bevacizumab in patients with chemotherapy resistant CRC and positivity for MSI-like molecular signature. This is an international, open-label single arm (non-randomized), one-stage phase II trial.","dates":{"creation":"2017-11-15"},"accession":"2231288","cross_references":{"ClinicalTrials___gov":["NCT02982694"],"EU Clinical Trials Register":["2016-002001-19"]}}